A Study to Evaluate AVB-S6-500 with Paclitaxel vs Paclitaxel in Patients with Platinum-resistant Recurrent Ovarian Cancer


About this study

The purpose of this study is to evaluate AVB-S6-500 in combination with paclitaxel (Pac) in patients with platinum resistant recurrent ovarian cancer to compare the effectiveness and of AVB-S6-500 in combination with Pac versus placebo plus Pac.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Histologically confirmed and documented recurrent ovarian, fallopian tube, or peritoneal cancer. Only patients with high-grade serous adenocarcinoma histology are eligible.
  • Aged 18 years or older.
  • Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0 to 1.
  • Ability to understand the nature of this clinical study and willingness to give written informed consent and comply with scheduled visits, the treatment plan, laboratory tests, and follow-up visits.
  • Platinum-resistant disease (defined as progression within ≤ 6 months from completion of most recent platinum-containing regimen and calculated from the date of the last administered dose of platinum therapy).  Subject may have been treated with additional regimen(s) subsequent to determination of platinum resistance.
  • Available archived tumor tissue (a paraffin-embedded tissue block with sufficient tumor tissue for biomarker testing or unstained slides with sufficient tumor tissue may be substituted) or if archived tissue is not available, a fresh tumor biopsy is required.
  • Radiologic imaging with a computerized tomography (CT) scan or magnetic resonance imaging (MRI) (if cannot tolerate a CT scan) within 21 days of randomization. (If a site can document that the CT performed as part of the positron emission tomography [PET]- CT is of identical diagnostic quality to a diagnostic CT [with IV and oral contrast], then the CT portion of a PET-CT can be used).
  • Received at least 1 but not more than 4 prior therapy regimens since ovarian cancer diagnosis:
    • Maintenance therapy OR hormonal therapies should not be counted as a separate therapy;
    • Patients who have not received prior bevacizumab must be deemed medically inappropriate OR ineligible to receive bevacizumab, refused to receive bevacizumab, or been unable to receive bevacizumab due to lack of access.
  • Ovarian cancer that is measurable according to RECIST v1.1.
  • Normal gastrointestinal (GI) function.
  • Life expectancy > 3 months.
  • Negative serum pregnancy test within 7 days prior to randomization for females of childbearing potential (premenopausal and not surgically sterilized).
  • Adequate bone marrow function:
    • Absolute neutrophil count ≥ 1500/µL;
    • Platelet count ≥ 100,000/µL;
    • Hemoglobin ≥ 9.0 g/dL.
  • Adequate hepatic function:
    • Total bilirubin ≤ 1.5 × upper limit of normal (ULN);
    • Aspartate aminotransferase (AST) ≤ 3.0 × ULN*;
    • Alanine aminotransferase (ALT) ≤ 3.0 × ULN* .
    • *Unless liver metastases are present, in which case AST/ALT must be ≤ 5 × ULN.
  • Adequate renal function as determined by calculated or measured creatinine clearance ≥ 30 mL/min (using Cockcroft-Gault equation).
  • International normalized ratio (INR) ≤ 1.5 and activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN for subjects not on anticoagulation treatment. If subjects are on anticoagulation treatment, the corresponding laboratory values should be in therapeutic range for the respective agent.
  • Full recovery from all recent surgery on date of randomization; at least 1 week must have elapsed from the time of a minor surgery (port placement at any time is acceptable); from the date of randomization at least 21 days must have elapsed from the time of a major surgery. Must have fully recovered from all surgery-related toxicities to Grade 1 or less.
  • At least 28 days between termination of prior anticancer or hormonal therapy and first administration of AVB-S6-500.
  • Full recovery from all treatment-related toxicities to Grade 1 or less, except alopecia.

Exclusion Criteria:

  • Tumors in the breast or bone.
  • Untreated central nervous system (CNS) metastases (surgery and/or radiotherapy).  Subjects requiring corticosteroid therapy for the management of their treated CNS metastases may not be on > 10 mg/day prednisone or equivalent or have demonstrated signs or symptoms of neurologic instability for 28 days or less prior to randomization.
  • Primary platinum-refractory disease (defined as progression during or within 4 weeks after completion of the first platinum regimen).
  • Is being treated with concurrent anticancer therapy or other interventional treatments administered for their underlying ovarian cancer.
  • Received prior therapy with PAC in the platinum-resistant recurrent setting.
  • Clinically significant cardiac disease history including the following:
    • cardiac arrhythmia uncontrolled on medication;
    • unstable angina or clinically and/or electrocardiographically documented myocardial infarction within 6 months before randomization;
    • clinically significant valvular disease;
    • uncontrolled congestive heart failure;
    • corrected QT (QTc) prolongation > 470 msec;
    • clinically significant pericardial effusion.
  • History of a prior malignancy that was active (not indolent) within the previous 3 years, except for locally curable cancers that have been apparently cured such as basal or squamous cell skin cancer, superficial bladder cancer, endometrial stage 1 cancer, or carcinoma in situ of the cervix or breast.
  • History of or present CNS disease unrelated to cancer, unless adequately treated with standard medical therapy (e.g., uncontrolled seizures).
  • Nonhealing wound, ulcer, or bone fracture.
  • Evidence of clinically significant third spacing (e.g pleural effusions, ascites, anasarca, etc) that requires therapeutic intervention within 28 days prior to first dose of AVB-S6- 500.
  • Serious active infection requiring IV antibiotics and/or hospitalization within 7 days of randomization.
  • Known severe hypersensitivity to any of the study drugs or excipients, including history of allergic, anaphylactic, or other severe hypersensitivity reactions to fusion proteins, products containing Cremophor EL (e.g., cyclosporin for injection concentrate and teniposide for injection concentrate), or known hypersensitivity or allergy to Chinese hamster ovary cell products.
  • History of or evidence of any other medical conditions, psychiatric condition, physical examination, or laboratory findings that may interfere with the subject’s participation for the full duration of the Study Treatment, affect subject compliance, place the subject at high risk from treatment-related complications, confound the results of the study, or that is not in the best interest of the subject to participate.
  • Known active human immunodeficiency virus (HIV), hepatitis B, or hepatitis C, or any other known active viral illness such as coronavirus disease 2019 (COVID-19).
  • Patient currently breastfeeding or intending to become pregnant on study or within 6 months following discontinuation of Study Treatment. 16. Ever participated in a study with AVB-S6-500.

Eligibility last updated 1/19/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Andrea Wahner Hendrickson, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office


More information


Publications are currently not available

Mayo Clinic Footer